Constantly researching new treatments to help people lead vital lives.

Aytu BioPharma is committed to studying new treatments to make people’s lives better. Our pipeline and our focus on research are growing.

Aytu BioPharma Pipeline Overview

Current Pipeline

AR101 (enzastaurin)

AR101 (enzastaurin) is a pivotal study-ready therapeutic candidate initially targeting the treatment of vascular Ehlers-Danlos Syndrome (VEDS)

Healight (endotracheal light catheter)

Study being conducted using endotracheal UVA application on COVID-19, to determine safety and efficacy of novel approach to antimicrobial treatment via phototherapy on internal organs.

Business Development

Partnering for growth and improving patient health.

Aytu BioPharma is constantly exploring alliances to strengthen our product portfolio. We’re actively seeking to license and/or acquire specialty products and technologies that fit our strategic focus – with an emphasis on products that fulfill unmet needs and improve over existing therapies. We are committed to improving patients’ health worldwide by forging strong partnerships. If you are interested in discussing product opportunities, please contact us today.

Expanded Access Policy

Expanded access, also called compassionate use, enables patients with serious or immediately life-threatening diseases who do not meet the enrollment criteria for clinical trials in progress to gain access to investigational treatments. At this time, Aytu BioPharma does not offer an expanded access program and does not accept expanded access requests. We believe that investigational drugs should be studied in patients as part of clinical trials designed to produce data on safety and efficacy that may be used to support approval of the product, thereby leading to its broader availability for patients in need of treatment. Aytu strongly encourages patients to speak with their treating physicians and when possible to participate in clinical trials. Aytu is aware that in rare cases patients with serious life-threatening diseases are unable to participate in clinical trials and may have exhausted all available therapies. In these rare cases, Aytu may consider providing an investigational product outside of a clinical trial. However, we currently do not have an expanded access program that allows patients to have access to our investigational products prior to FDA approval. As authorized by the 21st Century Cures Act, Aytu may revise this expanded access policy at any time. Additionally, the posting of this policy by Aytu shall not serve as a guarantee of access to any specific investigational drug by any individual patient. In the event Aytu decides to consider expanded access, we will evaluate and respond to each request that it receives on a case-by-case basis. Reference information about our investigational drugs and ongoing clinical trials can be found on https://www.aytubio.com and https://clinicaltrials.gov. If you have additional questions, please speak with your physician, or contact us at ExpandedAccess@aytubio.com.